Low-dose CT, from three sides of the same scan

Low-dose CT sounds like a setting. It is not. It is a target a department commits to, a set of decisions a radiographer makes on every patient, and a number a patient will ask you about while lying on the table with their arms above their head.

Those three views of the same exam rarely get discussed together. The dose report goes to the physicist. The protocol conversation happens between the lead radiographer and the radiologist. The patient gets thirty seconds and a reassuring sentence. Everyone is doing their part properly, and the parts still do not always line up.

This piece walks the same scan past all three.

Typical published values · varies by scanner and patient · log scale

How low is low, in numbers people actually publish

There is no single threshold that makes a scan low dose. What exists instead is a set of targets from the bodies that write practice parameters, and they are close enough to each other to be useful.

For lung cancer screening, the American College of Radiology suggests a CTDI_vol at or below 3 mGy for a standard-sized patient, which works out at roughly 1 mSv of effective dose over a normal chest scan length. The AAPM's screening protocols put the same figure alongside a DLP ceiling of about 75 mGy·cm for patients in the 70 to 90 kg range. The European Society of Thoracic Imaging goes further and bands the target by weight, proposing something in the order of 0.4, 0.8 and 1.6 mGy for patients under 50 kg, 50 to 80 kg, and over 80 kg, which corresponds to an effective dose nearer 0.7 mSv.

For context, the average effective dose measured across the National Lung Screening Trial for average-sized participants was about 1.4 mSv. Ultra-low-dose chest protocols, the ones that came into wide use during COVID, sit lower still, in the region of half a millisievert. A standard diagnostic chest CT is usually a few times higher than any of these.

Here is the part that matters more than the target itself. A multi-centre comparison of real-world screening protocols found significant variation in CTDI_vol between centres running the same programme, driven by centre, kVp, mAs and patient factors. The guideline number is not what patients receive. What patients receive is whatever the local protocol, the local scanner and the person positioning them produce on the day.

Low dose is not a number you agree to. It is a number you keep hitting, on a Tuesday afternoon, on the third scanner, with a patient who cannot lift their left arm.

Same exam, three scorecards

One scan, three sets of priorities

Stakeholder 01

The department

Counts dose in DRLs, audit reports and accreditation. Wants consistency across scanners and a list that runs on time.

Stakeholder 02

The radiographer

Counts dose in centring, scan length, arm position and recon choice — decisions made in the ninety seconds before the scan starts.

Stakeholder 03

The patient

Counts dose in whether to worry, how long it takes, and whether they have to come back and do it again.

What it changes for the department

For whoever runs the CT service, low dose is mostly a governance problem wearing a physics costume.

Dose becomes a number you have to defend

Once a department commits to a low-dose target, that target gets audited. Diagnostic reference levels, dose-monitoring software, accreditation reviews and screening programme requirements all turn dose from something implicit into a metric with your name attached. That is a good thing, and it changes the internal conversation. The question stops being "did the images look alright" and becomes "why does scanner two run 40% higher than scanner one on the same protocol".

That question usually has a boring answer. A protocol was copied across at commissioning and then edited on one scanner only. A locum changed a preset. One room has an older tube and a different reconstruction option. The audit does not fix this. The audit finds it, and then somebody has to own protocol governance as an actual job.

Screening turns CT into a production line

A lung screening programme is a different animal from diagnostic CT. The USPSTF currently recommends annual low-dose CT for adults aged 50 to 80 with a 20 pack-year history who still smoke or quit within the past 15 years, and comparable programmes are running or building across Europe and Asia. The scans themselves are short and simple. The workload sits everywhere else: eligibility checks, recall tracking, Lung-RADS categorisation, nodule follow-up scheduling, and the incidental findings that a chest CT hands you whether or not you wanted them.

For the department the practical consequence is that screening slots need protocol discipline more than they need scanner power. Every scan is on the same body region, at the same target dose, on patients you will scan again next year. Consistency between visits is what makes nodule volumetry mean anything.

The quiet operational wins

Two benefits get less attention than they should. Lower tube output means less thermal load per exam, which matters for tube life and for keeping a busy list moving without waiting on cooling. And a well-run low-dose protocol usually reduces the friction around justification, because the "is this scan worth the dose" conversation gets easier when the dose in question is a millisievert.

What it changes for the radiographer

This is where the target either happens or does not. And the levers are not the exotic ones.

Centring is the cheapest dose reduction available

If a patient is not at isocentre, the bowtie filter is not doing what it was designed to do and the AEC is reading a distorted topogram. Phantom work has put the surface dose penalty at roughly 13%, 33% and 51% for vertical errors of 2, 4 and 6 cm. One clinical series found that 46% of adult body scans were 2 to 6 cm off in elevation, sitting on average about 23 mm below the centre of rotation.

That is not an exotic failure. That is a table height set by eye on a busy list.

Phantom data · magnitude varies with patient size and scanner

Scan length is dose nobody argues about

Every extra centimetre of z-coverage is dose, plus the over-ranging at each end of a helical acquisition. Trimming a chest that has crept up into the neck or down over the liver is free dose reduction with no image quality cost at all. It is also the easiest thing to let slide when you are planning off a topogram in a hurry.

Arms, jewellery, and the things that force a repeat

Arms down through a chest scan add attenuation, drive the AEC up and produce streaks through the exact region you are trying to assess. If the patient genuinely cannot raise them, that is a clinical constraint and you work around it. If they simply were not asked properly, that is a dose penalty you chose.

The shielding conversation has changed

The AAPM's 2019 position statement recommended discontinuing routine gonadal and fetal shielding in x-ray based imaging, and it has since been endorsed by the ACR and others, with a supporting NCRP statement following in 2021. The reasoning is worth being able to explain: shields give negligible benefit at diagnostic doses, they can obscure anatomy and force a repeat, and inside the scan field they can interfere with AEC and actually increase dose.

Local regulations still vary, and some states and countries have not moved. But the radiographer is now the person who has to explain to a patient why the lead apron they remember from ten years ago is not coming out. That is a communication skill, and it is part of dose optimisation whether or not anyone put it in the protocol.

Reconstruction is now yours to choose

Iterative and deep-learning reconstruction are what make aggressive low-dose protocols viable in the first place. Which strength, which kernel, which recon series goes to PACS: these are dose decisions, because they determine how far the mAs could come down in the first place. If the recon setting on your console is whatever the last shift left there, the protocol is not really being run as designed.

The levers, and who actually holds them

Lever	Held by	Effect	The catch
Justification	Referrer / radiologist	The only 100% dose reduction there is	Outside the radiographer's control, but not outside their voice
Protocol design	Lead radiographer + physicist	Sets the target everyone else works to	Drifts between scanners unless somebody owns it
Centring	Radiographer	Up to ~50% surface dose at 6 cm off	Invisible on the finished image; nobody audits it
Scan length	Radiographer	Directly proportional; plus over-ranging	Easy to over-cover when planning in a rush
kV and AEC settings	Protocol + radiographer	Large, especially with iodine at lower kV	Penetration and noise limits in larger patients
Reconstruction	Radiographer	Enables the low mAs to be diagnostic at all	Texture change; low-contrast detail needs checking
Not repeating	Everyone	Avoids doubling the whole exam	Depends on every row above being right first time

What it changes for the patient

Patients do not ask about CTDI_vol. They ask a version of one of three questions: is this going to hurt me, why do I need it, and how long will it take.

Answering the dose question without doing damage

There are two bad answers. "It's nothing, don't worry about it" is dismissive and, for a patient who has read something online, not credible. Reciting an effective dose in millisieverts to somebody who has never heard the unit is worse, because it sounds precise and communicates nothing.

The comparison that actually lands is background radiation. A screening chest CT in the region of 1 mSv sits at roughly a third of what an average person in the US receives from natural background in a year. That framing is honest, it is proportionate, and it does not pretend the dose is zero.

What it should not turn into is a promise. The risk at these levels is small and genuinely uncertain, and a radiographer is not the right person to be quantifying an individual's cancer risk at the scanner door. "Small, and much smaller than it used to be, and smaller than the reason we're scanning you" is a truthful sentence. Anything more precise belongs with the referrer.

Low dose is not only about radiation

For the person on the table, the improvements that came with low-dose protocols are often felt as something else entirely. Faster scanners mean shorter breath-holds. Better reconstruction means a scan that would once have needed a repeat now goes through first time. Fewer repeats means less time on a cold table with their arms up, which for an elderly patient or someone in pain is the thing they will actually remember about the visit.

Screening brings its own harms, and they are not radiation

If you work in a screening programme, this matters. The dose is about a millisievert. The real burdens for participants are false positives, the follow-up scans they trigger, incidental findings on other organs, and the months of low-grade worry between a nodule being seen and being cleared. Those are the harms the programme is designed to manage, and they are the ones patients will ask you about after the scan while they are putting their shoes on.

Being able to say "most nodules we find are not cancer, and the follow-up is how we tell" is a more useful thing to have ready than a dose figure.

For the patient, a low-dose scan that has to be repeated is not a low-dose scan. It is two scans and a second trip.

The three views do not always agree

Most dose guidance is written as though everyone wants the same thing. In a working department they do not, quite.

The way through both is the same, and it is unglamorous: the dose target has to travel with the clinical question, and the person at the console has to understand the target well enough to know when it does not apply. That is judgement, not a preset.

Why this is hard to teach on a real scanner

Every dose lesson worth learning involves getting it wrong once. Scan a patient 4 cm off isocentre and look at the dose report. Halve the mAs and find out which structures disappear first. Over-cover a chest by six centimetres and see the DLP move. Turn the recon strength down and watch a protocol that seemed fine at low dose stop being diagnostic.

None of those experiments are available to you on a department scanner, for the obvious reason. They are the exact things you are not allowed to do to a real patient, which is why most radiographers learn dose optimisation as a set of rules handed down rather than as something they have felt.

Simulation is the only place that experiment is free. ScanFlo CT runs kVp, mAs, pitch, scan length and reconstruction with live CTDI_vol and DLP feedback, so you can make the mistake, read the dose report, and see the image quality consequence side by side. The cost of a wrong answer is that you learn something.

Where it all lands

Low-dose CT is usually presented as a technical achievement, and it is one. Better detectors, tube current modulation, tin filtration, iterative and deep-learning reconstruction have all pushed the achievable dose down by a large factor within a working career.

But the achievement only reaches the patient through a department that keeps its protocols honest across every scanner, and a radiographer who centres properly, plans tightly, chooses the right recon and gets it right first time. The technology sets what is possible. The three people in this article decide what actually happens.

Which is a decent argument for talking about dose as an operational subject rather than a physics one.

A note on numbers. Dose figures here are typical published values for standard-sized adults and vary with scanner, protocol and patient size. Screening eligibility criteria and shielding regulations differ by country and, in some cases, by state or region. Always follow your local protocols, national guidance and departmental DRLs.

Sources

• USPSTF — Lung cancer screening recommendation
• Radiology: Imaging Cancer — Two decades of low-dose CT screening evidence
• AJR — Estimated radiation dose in the National Lung Screening Trial
• Real-world multi-centre comparison of LDCT screening protocols
• AJR — Effect of patient centering on dose and image noise in chest CT
• AAPM — Position statement on patient gonadal and fetal shielding
• AAPM CARES — Patient shielding FAQs